Gingival-derived mesenchymal stem cells alleviate allergic asthma inflammation via HGF in animal models

作者：Qiannan Fang, Wenbin Wu, Zexiu Xiao, Donglan Zeng, Rongzhen Liang, Julie Wang, Jia Yuan, Wenru Su, Xiang Xu, Yue Zheng, Tianwen Lai, Jianbo Sun, Qing‐Ling Fu, Song Guo Zheng · 发表于：iScience · 年份：2024 · DOI：10.1016/j.isci.2024.109818 · 被引用次数：11 · 研究领域：Mesenchymal stem cell research、Fibroblast Growth Factor Research、Periodontal Regeneration and Treatments

Allergic asthma is a chronic non-communicable disease characterized by lung tissue inflammation. Current treatments can alleviate the clinical symptoms to some extent, but there is still no cure. Recently, the transplantation of mesenchymal stem cells (MSCs) has emerged as a potential approach for treating allergic asthma. Gingival-derived mesenchymal stem cells (GMSCs), a type of MSC recently studied, have shown significant therapeutic effects in various experimental models of autoimmune diseases. However, their application in allergic diseases has yet to be fully elucidated. In this study, using an OVA-induced allergic asthma model, we demonstrated that GMSCs decrease CD11b + CD11c + proinflammatory dendritic cells (DCs), reduce Th2 cells differentiation, and thus effectively diminish eosinophils infiltration. We also identified that the core functional factor, hepatocyte growth factor (HGF) secreted by GMSCs, mediated its effects in relieving airway inflammation. Taken together, our findings indicate GMSCs as a potential therapy for allergic asthma and other related diseases.